Can CM577 regimen of adjuvant nivolumab s/p neoadjuvant chemoRT with residual disease following surgery be extrapolated to patients with R1 resection unable to undergo re-resection?

This is an excellent question and, of course, one for which there are no data. So, unburdened by data, I'm free to offer my personal opinion. I think all of us would value other comments and responses to this question as well.

I think that this question also applies to those patients who achieve a cl...

While CheckMate 577 was not designed to answer this question, my inclination is that adjuvant nivolumab could help patients who had an R1 resection and I would strongly consider this approach. However, prior to starting a patient who underwent an R1 resection on adjuvant nivolumab, I think these pat...

Unfortunately, all patients that enrolled in CM577 had an R0 surgical resection so we do not have data on the role of adjuvant PD-1 inhibitors in those patients who had an R1 resection.